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Identity 
Other names: GIF, GLIF, MMIF 




0,84 kb; mRNA: 561 bp; 3 Exons. 
Transcription 
The promoter region contains no TATA box. 
Pseudogene 
There are no MIF pseudogenes in the human genome. 




MIF is comprised of 115 amino acids with a molecular 
weight of 12,5 kDa (Weiser et al., 1989). In addition, 
research on the secondary structure revealed the 
existence of two antiparallel alpha-helices and six beta-
pleated sheets with a high degree of similarity to MHC 
molecules (Suzuki et al., 1996). MIF acts as a pro-
inflammatory protein, exists as a homo-trimer and 





Intracellular, cytoplasm, cytosolic, near the plasma 
membrane, perinuclear. 
Function 
MIF monomers are able to align in order to form a 
homotrimeric molecule that is homologous to the 
enzyme D-Dopachrome-tautomerase (Sun et al., 1996). 
From this structural analysis, some researches 
suggested that MIF may also display enzymatic activity 
(Rosengren et al., 1996). To date, the physiological 
importance of this enzymatic activity has not yet been 
revealed. Interestingly, using ISO-1, a known inhibitor 
of the enzyme D-Dopachrome-tautomerase led to 
reduced activity of MIF (Lubetsky et al., 2002). 
Therefore, it was hypothesized that this enzymatic 
activity may be related to its proper functioning. The 
protein MIF is involved in inducing angiogenesis, 
promoting cell cycle progression, inhibiting apoptosis 
and inhibiting lysing of tumor cells by NK cells 
(Takahashi et al., 1998; Shimizu et al., 1999; Mitchell 
and Bucala, 2000; Morrison et al., 2001; Fingerle-
Rowson et al., 2003). Recently, the CD74 molecule has 
been suggested to act as a potential receptor for MIF 
(Leng et al., 2003). 
Homology 

















MIF is upregulated in tumors as well as precancerous 
lesions (Wilson et al., 2005). They examined patients 
suffering from adenomas. In addition, an animal model 
of adenomatous polyposis coli was used. In both 
settings, the authors describe an increase in MIF 
mRNA levels in the diseases group when this was 
compared to healthy controls. Interestingly, in a mouse 
model of intestinal tumorigenesis, MIF deletion leads 
to a significant decrease in tumor size. In addition, 
reduced angiogenesis was taking place. The 
involvement of MIF in angiogenesis was also shown by 
Ogawa et al., using a mouse model of colon cancer 
(Ogawa et al., 2000). The application of MIF 
antibodies leads to suppression of angiogenesis in this 
disease model. Further work by Sun et al. demonstrated 
an involvement of MIF in tumor cell migration (Sun et 
al., 2005). They used siRNA technique and were able 
to show inhibition of cell migration after addition of 
siRNA directed against MIF. In an animal model, they 
injected colon cancer cells into mice portal vein after 
pretreatment with siRNA. The number of liver 
metastases was significantly reduced in the pretreated 
model. In summary, there is sufficient evidence to 
assume a role of MIF in both angiogenesis and tumor 
cell migration in colon cancer (Bach et al., 2009). 
Prognosis 
MIF expression is correlated with outcome (Legendre 
et al., 2003). Legendre et al. (2003) examined MIF 
distribution in 99 specimens of colorectal cancer. 
Primarily, they applied immunohistochemistry. They 
describe that the expression of MIF (and also galectin-
3) were increased in tumor tissue compared to normal 
tissue. For MIF, they could provide evidence that in 
Dukes C or D tumors with high concentration of MIF, 
this was associated with significantly better prognosis 
than in tumors with low MIF concentrations. They 
suggest that MIF could be used to identify patients at 
risk needing more aggressive treatment strategies. 
Melanoma 
Disease 
MIF inhibits lysis of melanoma cells by NK cells 
(Repp et al., 2000). This was shown by Apte et al., who 
demonstrated that NK cells are prevented from cell 
lysis of melanoma cells (Apte et al., 1998). This 
underlines the influence of MIF on the immune system. 
In addition, it enhances tumor cell proliferation. 
Prognosis 
To date, there is no clear association between MIF 





MIF was shown to be abundant in prostate cancer 
(Meyer-Siegler et al., 1998). In addition, MIF was 
shown to influence cell viability and invasiveness. 
Specifically in prostate cancer, androgen independent 
cancer cells relied on MIF activated pathways in order 
to grow and for their invasiveness. Androgen 
dependent tumor cells did not require these signal 
transduction pathways. Meyer-Siegler et al. were able 
to show that CD74, a potential MIF surface receptor, 
was abundant in androgen-independent tumor cells 
(Meyer-Siegler et al., 2006). Receptor blockage as well 
as strategies to reduce MIF resulted in decreased cell 
proliferation, MIF secretion and invasion of tumor 
cells. 
Prognosis 
MIF expression clearly correlates with disease 
progression (Meyer-Siegler et al., 2002). In androgen 
independent prostate cancer, cells require MIF 
activated signal transduction pathways for invasion and 
growth, in contrast to androgen dependent tumor cells. 
In a study by Meyer-Siegler, serum MIF concentration 
was measured in dependence of Gleason score in 
patients with prostate cancer (Meyer-Siegler et al., 
2002). They were able to show that increased MIF 
concentration is positively associated with a Gleason 
Score greater than 5. In addition, even in patients with 
normal prostate-specific antigen, MIF concentration 
was increased. From their data, they conclude that MIF 
may be a suitable biomarker for prostate cancer. 
Lung adenocarcinoma 
Note 
Treatment with siRNA leads to a significant reduction 
in cell invasiveness and cell migration (Rendon et al., 
2007), paralled by a reduction of a Rho GTPase. MIF 
overexpression led to adverse effects. 
Prognosis 
Kamimura and colleagues analysed the role of MIF 
with respect to prognosis in lung cancer (Kamimura et 
al., 2000). They used immunofluorescence staining in 
primary lung tissue that had been obtained surgically. 
They were able to demonstrate a diffuse staining 
pattern within the cytoplasm. Furthermore, sometimes, 
a nuclear staining was also observed. Interestingly, the 
authors were able to demonstrate a correlation between 
a lack of nuclear staining and a poorer prognosis. 
From this observation, they concluded that MIF might 
play different roles with respect to subcellular 
localization. It needs to be mentioned however, that 
only thirty-eight cases were reviewed. 
Glioblastoma 
Note 
MIF is involved in angiogenesis and cell cycle 
regulation. It was demonstrated that MIF expression is 
induced following hypoxia and hypoglycemia (Bacher 
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et al., 2003), which are both considered activators of 
angiogenesis. Using immunofluorescence techniques, 
MIF could be demonstrated around necrotic tissue and 
in blood vessels surrounding tumor cells. Therefore it 
was concluded that neovascularization is enhanced by 
MIF. In line with this observation is the work published 
by Munaut et al. (2002). They demonstrated that there 
is a correlation between MIF expression and the 
expression of vascular endothelial growth factor 
(VEGF). They analysed primary glioblastoma tissue 
using RT-PCR and immmunohistochemistry and they 
were able to show a strong correlation between MIF 
expression and VEGF mRNA concentration. >From 
these data, it was suggested that there may be a 
common triggering factor. Inactivation of p53 may be 
of central importance, as it is a common event in 
glioblastoma progression (Bach et al., 2009). In 
addition, p53 inactivation is also involved in increased 
VEGF expression (Kieser et al., 1994). Since the 
angiogenic potential of a tumor is vital for formation of 




MIF expression and increased angiogenesis were also 
demonstrated in hepatocellular carcinoma following 
hypoxia (Hira et al., 2005). 
Prognosis 
MIF overexpression correlates with negative prognosis 
(Hira et al., 2005). 56 samples of hepatocellular 
carcinoma were analysed using Western blot and 
correlated these values with clinical parameters. In 
addition, they used immunohistochemistry. They 
showed that MIF expression was correlated with high 
alpha fetoprotein level and the recurrence of hepatic 
tumor. In addition, tumor free survival was reduced 
when MIF expression was increased. In addition, 
increased mRNA concentrations can be seen (Ren et 
al., 2003). 
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